When Paolo Paoletti joined GlaxoSmithKline in 2011 to build an oncology group, the number of cancer specialists on staff ranged in the dozens. By the time GSK decided to scrap the organization in a swap with Novartis, he had recruited 2,000 staffers around the world working on a full pipeline of therapies.
After winning FDA approval Monday, the latest multiple myeloma treatment--Empliciti, from Bristol-Myers Squibb and AbbVie--is about to hit the scene. And like its rivals in the field, it'll be pricey.
Partners Bristol-Myers Squibb and AbbVie picked up a speedy FDA approval for their cancer immunotherapy, preparing to launch a key cog in each company's oncology pipeline.
It's been more than three years since Amgen's multiple myeloma treatment Kyprolis won approval from U.S. regulators. Now, it's finally done the same in Europe--and with competition heating up across the pond, the go-ahead couldn't have come at a better time for the California biotech.
Takeda Pharmaceutical's top cancer prospect won a speedy FDA approval, wading into a crowded market for multiple myeloma treatments with hopes of duplicating the success of Velcade.
Johnson & Johnson's new multiple myeloma treatment Darzalex (daratumumab) scored a speedy FDA approval, entering a market that's already crowded with last-ditch treatments. But the company is hoping an impressive response rate will help the new med knock aside Celgene's Pomalyst and Amgen's Kyprolis in the battle for market share.
Johnson & Johnson scored an early FDA approval for its "breakthrough" blockbuster contender daratumumab, earning a swift OK as a new treatment for multiple myeloma four months ahead of the PDUFA date. The drug will be marketed as Darzalex.
A new drug for blood cancer from Bristol-Myers Squibb and AbbVie is on the fast track to FDA approval, winning a priority review to treat multiple myeloma.
The market for multiple myeloma drugs is poised for expansion, in part thanks to a globally aging population and improved diagnostic techniques. But new meds are doing their fair share, too, and they'll help push the market's value to nearly $9 billion in 2021, a new report says.
Takeda's top oncology prospect is moving toward approval in the European Union, as continental regulators have accepted the company's application and promised a shortened review period for the blood cancer treatment.